In conclusion, our study suggests that MYC amplification in HNSCC, while a relatively uncommon occurrence, may play a key role not only in chemo and radioresistance but suggests that acquired clonal alteration may drive resistance to immunotherapy through a variety of potential immune suppressive mechanisms, warranting further study. The gene discussed is MYC; the disease is head and neck squamous cell carcinoma.